Cagrilintide Research Notes
Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for Cagrilintide. Research use only.
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.
Recent publications describe cagrilintide through amylin-receptor pharmacology, receptor structure, and peptide-development reviews.
Questions covered by the selected literature
- Which amylin receptor subtypes are discussed
- What structural studies report about receptor activation
- How review articles distinguish mechanism from clinical claims
Evidence limits
These records include mechanistic and review literature. They do not convert a research-use catalog item into an approved medication or provide product-use guidance.
A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.
Selected PubMed sources
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.. EBioMedicine. 2025 Aug. PMID: 40609154.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.. Acta Pharmacol Sin. 2026 Jan. PMID: 40847076.
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.. Vascul Pharmacol. 2026 Mar. PMID: 41344603.
BioPep USA record
BioPep USA currently lists Cagrilintide. Use the product page for current options and the documentation page for lot records.
Last reviewed: July 20, 2026.
